Hypertrophic Cardiomyopathy Models

Our Model Offerings

• Transgenic Models
  Genetically engineered mice and rats carrying well‑established human HCM mutations that develop progressive hypertrophy, hypercontractility, and impaired relaxation in a genotype‑dependent manner. These models are available as constitutive, inducible, or knock‑in strains on defined genetic backgrounds.
• Surgery‑Induced Models
  Transverse aortic constriction (TAC) or suprarenal banding in mice/rats, which creates pressure overload and induces concentric hypertrophy, neurohormonal activation, and eventual transition to heart failure. The severity and duration of constriction can be titrated to mimic early compensated HCM or advanced decompensated stages.
• Drug‑Induced Models
  Chronic administration of β‑adrenergic agonists (e.g., isoproterenol), angiotensin II, or thyroid hormone analogues that provoke cardiac hypertrophy, myocyte necrosis, and perivascular fibrosis—reproducing the oxidative stress and metabolic derangements seen in HCM, but without genetic background constraints. These models allow rapid, cost‑effective screening and are readily reversible upon drug withdrawal.

You might be interested in...